Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITRM NASDAQ:KLTO NASDAQ:SNTI NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITRMIterum Therapeutics$0.68+0.2%$0.79$0.61▼$3.02$32.26M3.04607,476 shs245,922 shsKLTOKlotho Neurosciences$0.59-0.8%$0.93$0.11▼$3.91$35.93M10.7816.08 million shs1.55 million shsSNTISenti Biosciences$1.36+0.7%$1.70$1.26▼$16.94$35.58M2.06170,499 shs98,482 shsVIVSVivoSim Labs$4.78+14.1%$2.11$1.41▼$21.96$12.43M1.11426,687 shs388,019 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITRMIterum Therapeutics0.00%+0.63%-20.92%-31.75%-37.39%KLTOKlotho Neurosciences0.00%+21.67%-31.38%-64.45%+59,019,900.00%SNTISenti Biosciences0.00%-2.88%-11.18%-52.80%-56.03%VIVSVivoSim Labs0.00%+66.93%+136.72%+172.18%+418,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITRMIterum Therapeutics$0.68+0.2%$0.79$0.61▼$3.02$32.26M3.04607,476 shs245,922 shsKLTOKlotho Neurosciences$0.59-0.8%$0.93$0.11▼$3.91$35.93M10.7816.08 million shs1.55 million shsSNTISenti Biosciences$1.36+0.7%$1.70$1.26▼$16.94$35.58M2.06170,499 shs98,482 shsVIVSVivoSim Labs$4.78+14.1%$2.11$1.41▼$21.96$12.43M1.11426,687 shs388,019 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITRMIterum Therapeutics0.00%+0.63%-20.92%-31.75%-37.39%KLTOKlotho Neurosciences0.00%+21.67%-31.38%-64.45%+59,019,900.00%SNTISenti Biosciences0.00%-2.88%-11.18%-52.80%-56.03%VIVSVivoSim Labs0.00%+66.93%+136.72%+172.18%+418,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITRMIterum Therapeutics 3.00Buy$9.001,215.79% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/ASNTISenti Biosciences 3.00Buy$8.50525.00% UpsideVIVSVivoSim Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VIVS, ITRM, KLTO, and SNTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AKLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/ASNTISenti Biosciences$2.56M13.90N/AN/A$5.31 per share0.26VIVSVivoSim Labs$142K87.52N/AN/A$5.54 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)KLTOKlotho Neurosciences-$6.15M-$0.45N/A∞N/AN/A-325.88%-242.15%N/ASNTISenti Biosciences-$52.79M-$8.95N/AN/AN/AN/A-223.98%-76.02%11/13/2025 (Estimated)VIVSVivoSim Labs-$2.48M-$10.20N/A∞N/A-1,396.48%-32.95%-21.31%N/ALatest VIVS, ITRM, KLTO, and SNTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025KLTOKlotho NeurosciencesN/A-$0.12N/A-$0.12N/AN/A8/12/2025Q1 2026VIVSVivoSim LabsN/A-$1.14N/A-$1.14N/A$0.04 million8/7/2025Q2 2025SNTISenti Biosciences-$0.58-$0.56+$0.02-$0.56$1.30 million$0.50 million8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITRMIterum TherapeuticsN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITRMIterum TherapeuticsN/A2.692.52KLTOKlotho NeurosciencesN/A135.73135.73SNTISenti BiosciencesN/A3.263.26VIVSVivoSim LabsN/A4.524.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITRMIterum Therapeutics9.21%KLTOKlotho Neurosciences20.07%SNTISenti Biosciences25.73%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipITRMIterum Therapeutics2.40%KLTOKlotho Neurosciences26.70%SNTISenti Biosciences3.12%VIVSVivoSim Labs3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITRMIterum Therapeutics1047.17 million46.04 millionNot OptionableKLTOKlotho NeurosciencesN/A61.37 million44.99 millionN/ASNTISenti Biosciences426.16 million25.34 millionNot OptionableVIVSVivoSim Labs202.60 million2.50 millionN/AVIVS, ITRM, KLTO, and SNTI HeadlinesRecent News About These CompaniesFinancial Comparison: VivoSim Labs (VIVS) & The CompetitionSeptember 14 at 2:45 AM | americanbankingnews.comVivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | finanznachrichten.deVivoSim appoints Lialin as Chief Commercial OfficerAugust 14, 2025 | msn.comVivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing ServicesAugust 14, 2025 | quiverquant.comQVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | financialpost.comFVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | globenewswire.comVivoSim: Fiscal Q1 Earnings SnapshotAugust 12, 2025 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIVS, ITRM, KLTO, and SNTI Company DescriptionsIterum Therapeutics NASDAQ:ITRM$0.68 +0.00 (+0.22%) Closing price 03:59 PM EasternExtended Trading$0.68 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Klotho Neurosciences NASDAQ:KLTO$0.59 0.00 (-0.80%) As of 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Senti Biosciences NASDAQ:SNTI$1.36 +0.01 (+0.74%) Closing price 04:00 PM EasternExtended Trading$1.35 -0.01 (-0.74%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.VivoSim Labs NASDAQ:VIVS$4.78 +0.59 (+14.08%) As of 04:00 PM EasternOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
